<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22319592</article-id><article-id pub-id-type="pmc">3272014</article-id><article-id pub-id-type="publisher-id">PONE-D-11-17180</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0030854</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject></subj-group></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Membrane Receptor Signaling</subject></subj-group></subj-group></subj-group><subj-group><subject>Neuroscience</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Behavioral Pharmacology</subject></subj-group></subj-group><subj-group><subject>Mental Health</subject></subj-group></subj-group></article-categories><title-group><article-title>Noradrenergic &#x003b1;<sub>1</sub> Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial</article-title><alt-title alt-title-type="running-head">Noradrenergic Antagonist Blocks Cocaine Effects</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Newton</surname><given-names>Thomas F.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De La Garza</surname><given-names>Richard</given-names><suffix>II</suffix></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kosten</surname><given-names>Thomas R.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mahoney</surname><given-names>James J.</given-names><suffix>III</suffix></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Haile</surname><given-names>Colin N.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">
<addr-line>Menninger Department of Psychiatry &#x00026; Behavioral Sciences, Baylor College of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Le Foll</surname><given-names>Bernard</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Centre for Addiction and Mental Health, Canada</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>tnewton@bcm.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TN RDG TRK JJM CNH. Performed the experiments: TN RDG GB JJM CNH. Analyzed the data: TN RDG. Contributed reagents/materials/analysis tools: TN RDG. Wrote the paper: TN RDG CH.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>3</day><month>2</month><year>2012</year></pub-date><volume>7</volume><issue>2</issue><elocation-id>e30854</elocation-id><history><date date-type="received"><day>7</day><month>9</month><year>2011</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Newton et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic &#x003b1;<sub>1</sub> receptor antagonist doxazosin on the positive subjective effects of cocaine.</p></sec><sec><title>Methods</title><p>Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin, with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with placebo saline randomly interspersed to maintain the blind.</p></sec><sec><title>Results</title><p>Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of &#x0201c;high&#x0201d;, &#x0201c;stimulated&#x0201d;, &#x0201c;like cocaine&#x0201d;, &#x0201c;desire cocaine&#x0201d;, &#x0201c;any drug effect&#x0201d;, and &#x0201c;likely to use cocaine if had access&#x0201d; (p&#x0003c;.001). Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of &#x0201c;stimulated&#x0201d;, &#x0201c;like cocaine&#x0201d;, and &#x0201c;likely to use cocaine if had access&#x0201d; (p&#x0003c;.05). There were trends for doxazosin to reduce ratings of &#x0201c;stimulated&#x0201d;, &#x0201c;desire cocaine&#x0201d;, and &#x0201c;likely to use cocaine if had access&#x0201d; (p&#x0003c;.10).</p></sec><sec><title>Conclusions</title><p>Medications that block noradrenergic &#x003b1;<sub>1</sub> receptors, such as doxazosin, may be useful as treatments for cocaine dependence, and should be evaluated further.</p></sec><sec><title>Trial Registration</title><p>Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01062945">NCT01062945</ext-link>
</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>A great deal of research aimed at developing treatments for cocaine dependence has focused on agents that directly or indirectly alter functioning of dopaminergic systems, as dopamine (DA) is known to play an important role in mediating cocaine's reinforcing effects <xref rid="pone.0030854-Wise1" ref-type="bibr">[1]</xref>. Progress has been limited, however, as DA antagonists are aversive and non-specifically disrupt behavior <xref rid="pone.0030854-Woolverton1" ref-type="bibr">[2]</xref>. Most direct DA agonists have proven ineffective as treatments for cocaine dependence <xref rid="pone.0030854-Soares1" ref-type="bibr">[3]</xref>, and indirect DA agonists such as amphetamine or methamphetamine, while effective for reducing cocaine use <xref rid="pone.0030854-Grabowski1" ref-type="bibr">[4]</xref>, <xref rid="pone.0030854-Mooney1" ref-type="bibr">[5]</xref>, have substantial abuse liability that limits their utility <xref rid="pone.0030854-Jasinski1" ref-type="bibr">[6]</xref>.</p><p>Genetic and pharmacological evidence has implicated noradrenergic mechanisms in mediating the effects of cocaine and other stimulants <xref rid="pone.0030854-Weinshenker1" ref-type="bibr">[7]</xref>. For example, animals which do not express the noradrenergic &#x003b1;<sub>1</sub> receptor (&#x003b1;<sub>1</sub>R) are insensitive to the locomotor activating effects of cocaine and amphetamine <xref rid="pone.0030854-Drouin1" ref-type="bibr">[8]</xref>, <xref rid="pone.0030854-Darracq1" ref-type="bibr">[9]</xref>, and treatment with the noradrenergic &#x003b1;<sub>1</sub>R antagonist prazosin blocks both cocaine-induced locomotor activation <xref rid="pone.0030854-Drouin2" ref-type="bibr">[10]</xref>, <xref rid="pone.0030854-Snoddy1" ref-type="bibr">[11]</xref> and cocaine-induced reinstatement of extinguished cocaine self-administration in rats <xref rid="pone.0030854-Zhang1" ref-type="bibr">[12]</xref>.</p><p>Prazosin is the prototypical &#x003b1;<sub>1</sub>R antagonist. Prazosin has an elimination half-life of 2-3 hours in humans <xref rid="pone.0030854-Jaillon1" ref-type="bibr">[13]</xref>, and this limits its potential clinical utility because most patients cannot reliably adhere to dosing regimens that require dosing throughout the day. Doxazosin is a newer &#x003b1;<sub>1</sub>R antagonist with an elimination half-life of 22 hours in humans <xref rid="pone.0030854-Elliott1" ref-type="bibr">[14]</xref>, allowing once-daily dosing. Although early reports indicated that doxazosin had poor brain penetration <xref rid="pone.0030854-PrysRoberts1" ref-type="bibr">[15]</xref>, <xref rid="pone.0030854-Guo1" ref-type="bibr">[16]</xref>, the side-effects of doxazosin, which include fatigue, dizziness, and somnolence, suggest that doxazosin acts centrally.</p><p>We assessed the impact of doxazosin treatment on cocaine's effects using a double-blind, placebo-controlled, within-subjects design in non-treatment-seeking, cocaine-dependent volunteers. We hypothesized that doxazosin treatment would attenuate the subjective effects of cocaine.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Participants</title><p>Non-treatment-seeking, cocaine-dependent participants were recruited through advertisements and were paid for their participation. They received $50 per day for inpatient components of the study and received a $100 completion bonus. All participants met DMS-IV criteria for cocaine dependence, were between 18 and 55 years old, had a history of using cocaine by the smoked or IV route, and normal laboratory evaluation, ECG, and vital signs. Exclusion criteria included a history of head trauma, epilepsy, dependence on drugs other than cocaine and nicotine, inability to detect effects of cocaine, or the presence of any other axis I psychiatric disorder. Serious medical conditions such as heart disease, AIDS, and asthma were also exclusionary. Concomitant use of psychotropic medications or medications affecting blood pressure was not allowed. This study was approved by the institutional review board of the Baylor College of Medicine and all participants gave informed consent.</p></sec><sec id="s2b"><title>Assessments</title><p>Clinical diagnosis was determined using the MINI <xref rid="pone.0030854-Sheehan1" ref-type="bibr">[17]</xref>. Mood was assessed using the Beck Depression Inventory <xref rid="pone.0030854-Beck1" ref-type="bibr">[18]</xref>. Heart rate and blood pressure were measured frequently throughout the study and at several time points following cocaine dosing. Subjective effects of cocaine were measured using visual-analogue scales anchored at 0 (no effect) and 100 (most ever). Ratings were obtained for &#x0201c;high&#x0201d;, &#x0201c;any drug effects&#x0201d;, &#x0201c;stimulated&#x0201d;, &#x0201c;good effects&#x0201d;, &#x0201c;like cocaine&#x0201d;, &#x0201c;bad effects&#x0201d;, &#x0201c;anxious&#x0201d;, &#x0201c;desire cocaine&#x0201d;, and &#x0201c;likely to use cocaine if had access&#x0201d;. Subjective effects ratings were obtained prior to cocaine dosing and at 5 min intervals until 55 min after dosing. Heart rate and blood pressure measures were also collected at the same time points.</p></sec><sec id="s2c"><title>Medications</title><p>Doxazosin 1 mg tablets were purchased commercially from Green Park Pharmacy, Houston TX. Doxazosin was over-encapsulated to mask study medication treatment and encapsulated placebo lactose served as the control. Sterile cocaine HCl for human use was provided by NIDA's medication supply program by RTI International, Research Triangle Park, NC. Sterile saline was used to dilute the cocaine to the desired concentration and also served as the placebo for cocaine.</p></sec><sec id="s2d"><title>Study Design</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0030854.s002">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0030854.s001">Protocol S1</xref>. The study employed a within-subjects, double-blind, placebo-controlled design. The order in which participants received doxazosin and placebo was counterbalanced across participants. At least 2 weeks separated study episodes to allow medication wash-out. After screening to assure that participants met inclusion and exclusion criteria, participants were enrolled and housed on the Research Commons of the Michael E. DeBakey VA Medical Center. Participants were monitored closely while inpatient and intermittent UAs were performed to ensure that participants remained abstinent for substances not administered as part of the protocol. Participants were discharged from the hospital between the study episodes. Study medication was started at one capsule per day in the morning and increased by one capsule every three days until participants reached four capsules per day. Resting and orthostatic blood pressure measurements were monitored frequently, as doxazosin can cause hypotension, especially after increases in the dose.</p></sec><sec id="s2e"><title>Cocaine Dosing</title><p>When participants reached 4 mg doxazosin/placebo/d (Day 10 of study medication treatment), participants received cocaine (20 and 40 mg, IV) in ascending order with a dose of saline randomly interspersed to maintain the blind. Two of the three doses were given in the morning, separated by 1 h. The third dose was given in the afternoon, several hours after the previous dose. The three doses were sufficiently separated in time to allow effects to completely dissipate between doses <xref rid="pone.0030854-Newton1" ref-type="bibr">[19]</xref>. Participants were monitored and discharged from the hospital when stable, generally after 6&#x02013;8 h.</p></sec><sec id="s2f"><title>Outcomes</title><p>The primary outcome was the impact of doxazosin treatment on the cardiovascular and subjective effects of cocaine. We also assessed the tolerability of doxazosin treatment alone in this population, with particular attention to effects of doxazosin treatment on blood pressure. We planned on enrolling 15 participants with the goal of obtaining at least 10 completers.</p></sec><sec id="s2g"><title>Statistical Analysis</title><p>For subjective effects measures, the area under to time-effect curve (AUC) was calculated using the trapezoidal rule <xref rid="pone.0030854-Chiou1" ref-type="bibr">[20]</xref>. For both morning cocaine doses, ratings collected 15 min prior to the first cocaine dose were used as baseline. For the afternoon dose, ratings collected 15 min prior to the afternoon cocaine dose were used as baseline. A two-way repeated measures analysis of variance (ANOVA) was used to analyze effects of doxazosin (0 and 4 mg) on the subjective effects measured following cocaine at three dose levels (0, 20, 40 mg). When main effects were significant, we conducted pairwise multiple comparisons using the Holm-Sidak method so long as the overall significance level was p&#x02264;.05. For cardiovascular measures following cocaine dosing, repeated measures ANOVA were calculated, with time (pre-dose to 55 min after cocaine dose) being the repeated measure. We used a repeated measures analysis for cardiovascular measures rather than using the AUC approach because the peak values (e.g. of heart rate and blood pressure) reflect the maximum physiological effects of cocaine and we wanted to document how doxazosin impacted this. We also measured change in cardiovascular measures following study medication dosing at 8 am by comparing cardiovascular measures taken at 9 am to those taken prior to dosing at 7:30 am using a repeated measures ANOVA. The data were tested for normality using the Shapiro-Wilk normality test, and for equal variance using the Levene median test. Statistics were calculated using Sigmaplot version 12 (Systat Software, Inc, San Jose, CA).</p></sec></sec><sec id="s3"><title>Results</title><p>The numbers of participants screened, randomized, and the sample analyzed are shown in <xref ref-type="fig" rid="pone-0030854-g001">Figure 1</xref>. Participants' demographic and drug use characteristics are shown in <xref ref-type="table" rid="pone-0030854-t001">Table 1</xref>. Participants were middle-aged and used cocaine on average for more than a decade. Most used alcohol and marijuana frequently, though none met criteria for dependence. Most smoked cigarettes and met criteria for nicotine dependence.</p><fig id="pone-0030854-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g001</object-id><label>Figure 1</label><caption><title>CONSORT Flowchart.</title><p>Participant flowchart.</p></caption><graphic xlink:href="pone.0030854.g001"/></fig><table-wrap id="pone-0030854-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.t001</object-id><label>Table 1</label><caption><title>Demographic Characteristics.</title></caption><alternatives><graphic id="pone-0030854-t001-1" xlink:href="pone.0030854.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cocaine Users</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(N&#x0200a;=&#x0200a;13)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Gender (N)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">12 (92&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">1 (8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ethnicity (N)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">3 (23&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="left" rowspan="1" colspan="1">1 (8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">African American</td><td align="left" rowspan="1" colspan="1">9 (69&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (yrs)</bold>
</td><td align="left" rowspan="1" colspan="1">44.31&#x000b1;4.63</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education (yrs)</bold>
</td><td align="left" rowspan="1" colspan="1">12.46&#x000b1;1.81</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nicotine Use</bold>
</td><td align="left" rowspan="1" colspan="1">10 (77&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cocaine Use</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Years of use</td><td align="left" rowspan="1" colspan="1">18.23&#x000b1;5.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of days used last in last 30 days</td><td align="left" rowspan="1" colspan="1">15.85&#x000b1;7.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Grams/day</td><td align="left" rowspan="1" colspan="1">1.30&#x000b1;0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Route of Admin</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoked</td><td align="left" rowspan="1" colspan="1">13 (100&#x00025;)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Data in tables reflect mean &#x000b1; S. D.</p></fn></table-wrap-foot></table-wrap><p>Doxazosin treatment was well tolerated and no participant was discontinued from the study due to side-effects. No participant spontaneously reported sedation, a known side effect of doxazosin, though we did not rate sedation or query participants. Heart rate and blood pressure were not significantly affected. Heart rate and blood pressure measures on the final day of treatment with each doxazosin dose are shown in <xref ref-type="table" rid="pone-0030854-t002">Table 2</xref>. There were no significant differences between measures taken during placebo and doxazosin treatment (p&#x0003e;.10). Change in heart rate and blood pressure following study medication dosing on the first day of treatment with each dose of study medication, when the largest effects would be expected, are shown in <xref ref-type="table" rid="pone-0030854-t003">Table 3</xref>. Doxazosin and placebo both produced minimal changes in blood pressure measured following study medication dosing on the first day of treatment with each dose of study medication (p&#x0003e;.10).</p><table-wrap id="pone-0030854-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.t002</object-id><label>Table 2</label><caption><title>Heart rate and blood pressure during treatment with doxazosin.</title></caption><alternatives><graphic id="pone-0030854-t002-2" xlink:href="pone.0030854.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">1 mg</td><td align="left" rowspan="1" colspan="1">2 mg</td><td align="left" rowspan="1" colspan="1">3 mg</td><td align="left" rowspan="1" colspan="1">4 mg</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Heart Rate</td><td align="left" rowspan="1" colspan="1">70.15&#x000b1;12.37</td><td align="left" rowspan="1" colspan="1">75.39&#x000b1;13.05</td><td align="left" rowspan="1" colspan="1">79.38&#x000b1;10.28</td><td align="left" rowspan="1" colspan="1">83.08&#x000b1;14.87</td><td align="left" rowspan="1" colspan="1">83.08&#x000b1;10.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP</td><td align="left" rowspan="1" colspan="1">121.92&#x000b1;9.31</td><td align="left" rowspan="1" colspan="1">124.39&#x000b1;7.18</td><td align="left" rowspan="1" colspan="1">118.39&#x000b1;11.91</td><td align="left" rowspan="1" colspan="1">121.92&#x000b1;10.14</td><td align="left" rowspan="1" colspan="1">124.17&#x000b1;12.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BL</td><td align="left" rowspan="1" colspan="1">79.54&#x000b1;7.51</td><td align="left" rowspan="1" colspan="1">76.92&#x000b1;8.08</td><td align="left" rowspan="1" colspan="1">73.84&#x000b1;9.79</td><td align="left" rowspan="1" colspan="1">77.69&#x000b1;9.07</td><td align="left" rowspan="1" colspan="1">72.08&#x000b1;9.86</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Cardiovascular measures taken following 3 days of treatment with 1, 2, 3 mg/d of doxazosin and following 1 day of treatment with 4 mg doxazosin. None of the values differed from baseline (p&#x0003e;.05).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0030854-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.t003</object-id><label>Table 3</label><caption><title>Change in heart rate and blood pressure following dosing.</title></caption><alternatives><graphic id="pone-0030854-t003-3" xlink:href="pone.0030854.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Doxazosin</td><td align="left" rowspan="1" colspan="1">1 mg</td><td align="left" rowspan="1" colspan="1">2 mg</td><td align="left" rowspan="1" colspan="1">3 mg</td><td align="left" rowspan="1" colspan="1">4 mg</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Heart Rate</td><td align="left" rowspan="1" colspan="1">.61&#x000b1;10.1</td><td align="left" rowspan="1" colspan="1">&#x02212;2.92&#x000b1;13.6</td><td align="left" rowspan="1" colspan="1">6.08&#x000b1;12.01</td><td align="left" rowspan="1" colspan="1">5.08&#x000b1;9.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP</td><td align="left" rowspan="1" colspan="1">&#x02212;.15&#x000b1;8.25</td><td align="left" rowspan="1" colspan="1">&#x02212;1.46&#x000b1;8.38</td><td align="left" rowspan="1" colspan="1">&#x02212;2.15&#x000b1;9.22</td><td align="left" rowspan="1" colspan="1">&#x02212;.46&#x000b1;8.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BL</td><td align="left" rowspan="1" colspan="1">&#x02212;1.38&#x000b1;4.33</td><td align="left" rowspan="1" colspan="1">.69&#x000b1;8.62</td><td align="left" rowspan="1" colspan="1">.85&#x000b1;12.16</td><td align="left" rowspan="1" colspan="1">&#x02212;1.15&#x000b1;10.53</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Heart Rate</td><td align="left" rowspan="1" colspan="1">.23&#x000b1;9.43</td><td align="left" rowspan="1" colspan="1">2.54&#x000b1;15.40</td><td align="left" rowspan="1" colspan="1">1.61&#x000b1;13.20</td><td align="left" rowspan="1" colspan="1">&#x02212;2.15&#x000b1;9.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP</td><td align="left" rowspan="1" colspan="1">&#x02212;.46&#x000b1;1035</td><td align="left" rowspan="1" colspan="1">1.15&#x000b1;8.38</td><td align="left" rowspan="1" colspan="1">&#x02212;1.38&#x000b1;8.93</td><td align="left" rowspan="1" colspan="1">&#x02212;2.31&#x000b1;12.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BL</td><td align="left" rowspan="1" colspan="1">&#x02212;1.08&#x000b1;7.67</td><td align="left" rowspan="1" colspan="1">&#x02212;1.85&#x000b1;5.86</td><td align="left" rowspan="1" colspan="1">&#x02212;2.69&#x000b1;6.72</td><td align="left" rowspan="1" colspan="1">&#x02212;1.38&#x000b1;8.98</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Study medication was dosed at 8am and values represent change (9am minus 7:30am) in heart rate and blood pressure. Measures recorded during treatment with doxazosin did not differ from those recorded during treatment with placebo and no dose differed from another dose (p&#x0003e;.10).</p></fn></table-wrap-foot></table-wrap><p>Doxazosin had trend-level effects on systolic blood pressure following cocaine dosing (p&#x0003c;.09) but did not significantly affect diasystolic blood pressure or heart rate and there were no statistically significant interactions between cocaine dose and cardiovascular measures. Cardiovascular measures over the 55 min following cocaine dosing are shown in <xref ref-type="fig" rid="pone-0030854-g002">Figures 2</xref>, <xref ref-type="fig" rid="pone-0030854-g003">3</xref>, <xref ref-type="fig" rid="pone-0030854-g004">4</xref>.</p><fig id="pone-0030854-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g002</object-id><label>Figure 2</label><caption><title>Heart rate and blood pressure following cocaine dosing.</title><p>Cardiovascular measures are plotted as change from baseline following cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g002"/></fig><fig id="pone-0030854-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g003</object-id><label>Figure 3</label><caption><title>Heart rate and blood pressure following cocaine dosing.</title><p>Cardiovascular measures are plotted as change from baseline following cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g003"/></fig><fig id="pone-0030854-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g004</object-id><label>Figure 4</label><caption><title>Heart rate and blood pressure following cocaine dosing.</title><p>Cardiovascular measures are plotted as change from baseline following cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g004"/></fig><p>Cocaine produced increases in ratings for most subjective effects, including &#x0201c;high&#x0201d;, &#x0201c;any drug effect&#x0201d;, &#x0201c;stimulated&#x0201d;, and &#x0201c;good effects&#x0201d; (p&#x0003c;.001). There were significant effects of study drug treatment for ratings of &#x0201c;stimulated&#x0201d; (F&#x0200a;=&#x0200a;7.41, p&#x0200a;=&#x0200a;.019), &#x0201c;like&#x0201d; (F&#x0200a;=&#x0200a;5.17, p&#x0200a;=&#x0200a;.042), and &#x0201c;desire cocaine&#x0201d; (F&#x0200a;=&#x0200a;5.47, p&#x0200a;=&#x0200a;.037), and &#x0201c;likely to use cocaine if had access&#x0201d; (5.57, p&#x0200a;=&#x0200a;.036). For each of these variables, the assumptions regarding normal distributions of data were met. For all but &#x0201c;like&#x0201d; the equal variance assumption was met as well. These are shown in <xref ref-type="fig" rid="pone-0030854-g005">figures 5</xref>, <xref ref-type="fig" rid="pone-0030854-g006">6</xref>, <xref ref-type="fig" rid="pone-0030854-g007">7</xref>, <xref ref-type="fig" rid="pone-0030854-g008">8</xref>. <italic>Post hoc</italic> analysis (using the Holm-Sidak method) showed that doxazosin treatment reduced effects the effects of 20 mg cocaine on ratings of &#x0201c;stimulated&#x0201d; (t&#x0200a;=&#x0200a;2.20, p&#x0200a;=&#x0200a;.035), &#x0201c;like&#x0201d; (t&#x0200a;=&#x0200a;2.16, p&#x0200a;=&#x0200a;.037), and &#x0201c;likely to use cocaine if had access&#x0201d; (t&#x0200a;=&#x0200a;2.29, p&#x0200a;=&#x0200a;.028). These analyses showed that doxazosin treatment produced trend-level reductions in the effects of 40 mg cocaine on ratings of &#x0201c;stimulated&#x0201d; (t&#x0200a;=&#x0200a;1.78, p&#x0200a;=&#x0200a;.083), &#x0201c;desire cocaine&#x0201d; (t&#x0200a;=&#x0200a;1.96, p&#x0200a;=&#x0200a;.059), and &#x0201c;likely to use cocaine if had access&#x0201d; (t&#x0200a;=&#x0200a;1.78, p&#x0200a;=&#x0200a;.083). Doxazosin treatment did not have significant effects on ratings of &#x0201c;high&#x0201d;, &#x0201c;any drug effects&#x0201d; or other subjective effects ratings (not shown).</p><fig id="pone-0030854-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g005</object-id><label>Figure 5</label><caption><title>Subjective effects following cocaine dosing.</title><p>Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as &#x0201c;not effects&#x0201d; and 100 anchored as &#x0201c;most ever&#x0201d;. ANOVA showed that there were significant effects (p&#x0003c;.05) of medication on ratings of &#x0201c;Stimulated&#x0201d;, &#x0201c;Like Cocaine&#x0201d;, &#x0201c;Desire Cocaine&#x0201d;, and &#x0201c;Likely to Use Cocaine&#x0201d;. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g005"/></fig><fig id="pone-0030854-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g006</object-id><label>Figure 6</label><caption><title>Subjective effects following cocaine dosing.</title><p>Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as &#x0201c;not effects&#x0201d; and 100 anchored as &#x0201c;most ever&#x0201d;. ANOVA showed that there were significant effects (p&#x0003c;.05) of medication on ratings of &#x0201c;Stimulated&#x0201d;, &#x0201c;Like Cocaine&#x0201d;, &#x0201c;Desire Cocaine&#x0201d;, and &#x0201c;Likely to Use Cocaine&#x0201d;. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g006"/></fig><fig id="pone-0030854-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g007</object-id><label>Figure 7</label><caption><title>Subjective effects following cocaine dosing.</title><p>Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as &#x0201c;not effects&#x0201d; and 100 anchored as &#x0201c;most ever&#x0201d;. ANOVA showed that there were significant effects (p&#x0003c;.05) of medication on ratings of &#x0201c;Stimulated&#x0201d;, &#x0201c;Like Cocaine&#x0201d;, &#x0201c;Desire Cocaine&#x0201d;, and &#x0201c;Likely to Use Cocaine&#x0201d;. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g007"/></fig><fig id="pone-0030854-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0030854.g008</object-id><label>Figure 8</label><caption><title>Subjective effects following cocaine dosing.</title><p>Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with 0 anchored as &#x0201c;not effects&#x0201d; and 100 anchored as &#x0201c;most ever&#x0201d;. ANOVA showed that there were significant effects (p&#x0003c;.05) of medication on ratings of &#x0201c;Stimulated&#x0201d;, &#x0201c;Like Cocaine&#x0201d;, &#x0201c;Desire Cocaine&#x0201d;, and &#x0201c;Likely to Use Cocaine&#x0201d;. Post hoc analysis showed that the statistically significant effects were observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. &#x0002a; p&#x0003c;.05, &#x0002b; p&#x0003c;.10.</p></caption><graphic xlink:href="pone.0030854.g008"/></fig></sec><sec id="s4"><title>Discussion</title><p>Doxazosin treatment was well tolerated, as was expected from earlier studies in other normotensive populations <xref rid="pone.0030854-Kirby1" ref-type="bibr">[21]</xref>. Doxazosin treatment had very modest effects on heart rate and blood pressure. The blood pressure effects of cocaine are likely mediated by sympathetic outflow and by effects of epinephrine and NE on peripheral vasculature and the observed effects of doxazosin on the cardiovascular effects of cocaine are consistent with this.</p><p>Doxazosin treatment significantly attenuated several of the positive subjective effects produced by cocaine, including ratings of &#x0201c;stimulated&#x0201d; and &#x0201c;like cocaine&#x0201d;, though the results for like should be interpreted with caution due to statistical limitations. Doxazosin also attenuated ratings of &#x0201c;likely to use&#x0201d; an index of craving. The magnitude of the effect was substantial for some of the variables (for example, the effect size d for reductions in &#x0201c;stimulated&#x0201d; during doxazosin treatment following administration of 20 mg cocaine was 0.84, which is considered large <xref rid="pone.0030854-Cohen1" ref-type="bibr">[22]</xref>).</p><p>The usual dose of doxazosin for the treatment of hypertension is 8&#x02013;16 mg/d, which is several-fold higher than the dose we tested in this study, 4 mg/d. Further, though doxazosin 4 mg substantially attenuated many of the effects produced by 20 mg cocaine, this dose of doxazosin reduced the effects produced by 40 mg cocaine to a more modest extent. Higher doses of doxazosin would be expected to have a greater impact on the effects produced by a wider range of cocaine doses, including perhaps doses abused by cocaine users. These doses are thought to be in the 50 to 100 mg range, though there are no good data to base this estimate on. Nevertheless, that doxazosin antagonism of cocaine's was surmounted by the higher cocaine dose suggests a pharmacological dose-effect function and likely higher doses of doxazosin are needed for more complete antagonism.</p><p>These data are very much in keeping with data reported in rats by Zhang and colleagues <xref rid="pone.0030854-Zhang1" ref-type="bibr">[12]</xref>, who found that prazosin pretreatment dose-dependently attenuated cocaine-induced reinstatement of extinguished cocaine-seeking behavior. The &#x0201c;reinstatement model&#x0201d; is frequently put forward as a model for craving induced by drug, stress, or other factors <xref rid="pone.0030854-Shaham1" ref-type="bibr">[23]</xref>.</p><p>The report by Zhang and colleagues is somewhat at odds with older data reported by Woolverton <xref rid="pone.0030854-Woolverton2" ref-type="bibr">[24]</xref> who found that prazosin did not alter responding maintained by cocaine. Prazosin treatment thus produced differential effects on cocaine reinstatement compared to reinforcing effects of cocaine. Consistent with this dissociation, we found that doxazosin treatment reduced indices reflecting desirability of cocaine, such as &#x0201c;like&#x0201d; and &#x0201c;likely to use cocaine with access&#x0201d;, without affecting indices reflecting euphoria, such as &#x0201c;high&#x0201d;. Euphoric effects are thought to relate to reinforcing effects <xref rid="pone.0030854-Fischman1" ref-type="bibr">[25]</xref>, <xref rid="pone.0030854-Fischman2" ref-type="bibr">[26]</xref>, though they need not necessarily do so <xref rid="pone.0030854-Haney1" ref-type="bibr">[27]</xref>.</p><p>The dampening effects of doxazosin on ratings of &#x0201c;stimulated&#x0201d; that we observed may reflect doxazosin's specific effects on noradrenergic neurotransmission. Cocaine inhibits the reuptake of NE with nearly the same potency that it inhibits the reuptake of DA <xref rid="pone.0030854-Rothman1" ref-type="bibr">[28]</xref>. The present data complement earlier preclinical research <xref rid="pone.0030854-Weinshenker1" ref-type="bibr">[7]</xref>, and underscore the importance of noradrenergic mechanisms in mediating many of cocaine's effects.</p><p>It is not known precisely how doxazosin treatment modulates the subjective effects of cocaine. Noradrenergic &#x003b1;<sub>1</sub>Rs are expressed widely throughout the brain, most notably in the striatum and the prefrontal cortex (PFC) <xref rid="pone.0030854-Morrison1" ref-type="bibr">[29]</xref>. Acting within the PFC, doxazosin could block noradrenergically mediated release of DA in the fronto-accumbens circuit, blunting accumbal activation <xref rid="pone.0030854-Schroeder1" ref-type="bibr">[30]</xref>.</p><p>These data demonstrate, for the first time in humans, that an &#x003b1;<sub>1</sub>R receptor antagonist can attenuate several of the effects of cocaine. These findings parallel closely those previously reported in preclinical research, increasing confidence in the findings. Nevertheless, the sample size was relatively small and replication is needed. The dose of doxazosin used was at the low end of the therapeutic window, and higher doses should be tested. Other medications affecting adrenergic activation are used successfully in the treatment of hypertension <xref rid="pone.0030854-Waeber1" ref-type="bibr">[31]</xref> (also a noradrenergically-mediated phenomenon) and these might be assessed as possible treatments for cocaine dependence as well. Examples include other preparations of doxazosin, such as extended release doxazosin XL, &#x003b1;<sub>2</sub>R receptor agonists such as lofexidine, and other classes of antihypertensives, such angiotensin converting enzyme inhibitors (e.g. perindopril).</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0030854.s001"><label>Protocol S1</label><caption><p>
<bold>Trial Protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0030854.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0030854.s002"><label>Checklist S1</label><caption><p>
<bold>CONSORT Checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0030854.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to acknowledge the expert assistance of the BCM General Clinical Research Center nursing staff.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by grants from the National Institutes of Health, P50 DA18197 and M01 RR00188. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0030854-Wise1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wise</surname><given-names>RA</given-names></name><name><surname>Rompre</surname><given-names>PP</given-names></name></person-group>
<year>1989</year>
<article-title>Brain dopamine and reward.</article-title>
<source>Annu Rev Psychol</source>
<volume>40</volume>
<fpage>191</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">2648975</pub-id></element-citation></ref><ref id="pone.0030854-Woolverton1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woolverton</surname><given-names>WL</given-names></name><name><surname>Balster</surname><given-names>RL</given-names></name></person-group>
<year>1981</year>
<article-title>Effects of antipsychotic compounds in rhesus monkeys given a choice between cocaine and food.</article-title>
<source>Drug Alcohol Depend</source>
<volume>8</volume>
<fpage>69</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">7297414</pub-id></element-citation></ref><ref id="pone.0030854-Soares1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soares</surname><given-names>BG</given-names></name><name><surname>Lima</surname><given-names>MS</given-names></name><name><surname>Reisser</surname><given-names>AA</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name></person-group>
<year>2001</year>
<article-title>Dopamine agonists for cocaine dependence (Cochrane Review).</article-title>
<source>Cochrane Database Syst Rev</source>
<volume>4</volume>
</element-citation></ref><ref id="pone.0030854-Grabowski1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>J</given-names></name><name><surname>Rhoades</surname><given-names>H</given-names></name><name><surname>Stotts</surname><given-names>A</given-names></name><name><surname>Cowan</surname><given-names>K</given-names></name><name><surname>Kopecky</surname><given-names>C</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.</article-title>
<source>Neuropsychopharmacology</source>
<volume>29</volume>
<fpage>969</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="pmid">15039761</pub-id></element-citation></ref><ref id="pone.0030854-Mooney1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mooney</surname><given-names>ME</given-names></name><name><surname>Herin</surname><given-names>DV</given-names></name><name><surname>Schmitz</surname><given-names>JM</given-names></name><name><surname>Moukaddam</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>CE</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.</article-title>
<source>Drug Alcohol Depend</source>
<volume>101</volume>
<fpage>34</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">19058926</pub-id></element-citation></ref><ref id="pone.0030854-Jasinski1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jasinski</surname><given-names>DR</given-names></name></person-group>
<year>1991</year>
<article-title>History of abuse liability testing in humans.</article-title>
<source>British Journal of Addiction</source>
<volume>86</volume>
<fpage>1559</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="pmid">1786487</pub-id></element-citation></ref><ref id="pone.0030854-Weinshenker1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinshenker</surname><given-names>D</given-names></name><name><surname>Schroeder</surname><given-names>JP</given-names></name></person-group>
<year>2007</year>
<article-title>There and back again: a tale of norepinephrine and drug addiction.</article-title>
<source>Neuropsychopharmacology</source>
<volume>32</volume>
<fpage>1433</fpage>
<lpage>1451</lpage>
<pub-id pub-id-type="pmid">17164822</pub-id></element-citation></ref><ref id="pone.0030854-Drouin1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drouin</surname><given-names>C</given-names></name><name><surname>Darracq</surname><given-names>L</given-names></name><name><surname>Trovero</surname><given-names>F</given-names></name><name><surname>Blanc</surname><given-names>G</given-names></name><name><surname>Glowinski</surname><given-names>J</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates.</article-title>
<source>J Neurosci</source>
<volume>22</volume>
<fpage>2873</fpage>
<lpage>2884</lpage>
<pub-id pub-id-type="pmid">11923452</pub-id></element-citation></ref><ref id="pone.0030854-Darracq1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Darracq</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>G</given-names></name><name><surname>Glowinski</surname><given-names>J</given-names></name><name><surname>Tassin</surname><given-names>J-P</given-names></name></person-group>
<year>1998</year>
<article-title>Importance of the Noradrenaline-Dopamine Coupling in the Locomotor Activating Effects of D-Amphetamine.</article-title>
<source>J Neurosci</source>
<volume>18</volume>
<fpage>2729</fpage>
<lpage>2739</lpage>
<pub-id pub-id-type="pmid">9502830</pub-id></element-citation></ref><ref id="pone.0030854-Drouin2"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drouin</surname><given-names>C</given-names></name><name><surname>Blanc</surname><given-names>G</given-names></name><name><surname>Villegier</surname><given-names>AS</given-names></name><name><surname>Glowinski</surname><given-names>J</given-names></name><name><surname>Tassin</surname><given-names>JP</given-names></name></person-group>
<year>2002</year>
<article-title>Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics.</article-title>
<source>Synapse</source>
<volume>43</volume>
<fpage>51</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">11746733</pub-id></element-citation></ref><ref id="pone.0030854-Snoddy1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snoddy</surname><given-names>AM</given-names></name><name><surname>Tessel</surname><given-names>RE</given-names></name></person-group>
<year>1985</year>
<article-title>Prazosin: effect on psychomotor-stimulant cues and locomotor activity in mice.</article-title>
<source>Eur J Pharmacol</source>
<volume>116</volume>
<fpage>221</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">3878298</pub-id></element-citation></ref><ref id="pone.0030854-Zhang1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Kosten</surname><given-names>TA</given-names></name></person-group>
<year>2005</year>
<article-title>Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking.</article-title>
<source>Biol Psychiatry</source>
<volume>57</volume>
<fpage>1202</fpage>
<lpage>1204</lpage>
<pub-id pub-id-type="pmid">15866561</pub-id></element-citation></ref><ref id="pone.0030854-Jaillon1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaillon</surname><given-names>P</given-names></name></person-group>
<year>1980</year>
<article-title>Clinical pharmacokinetics of prazosin.</article-title>
<source>Clin Pharmacokinet</source>
<volume>5</volume>
<fpage>365</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">6994981</pub-id></element-citation></ref><ref id="pone.0030854-Elliott1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elliott</surname><given-names>HL</given-names></name><name><surname>Meredith</surname><given-names>PA</given-names></name><name><surname>Sumner</surname><given-names>DJ</given-names></name><name><surname>McLean</surname><given-names>K</given-names></name><name><surname>Reid</surname><given-names>JL</given-names></name></person-group>
<year>1982</year>
<article-title>A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.</article-title>
<source>Br J Clin Pharmacol</source>
<volume>13</volume>
<fpage>699</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="pmid">6123342</pub-id></element-citation></ref><ref id="pone.0030854-PrysRoberts1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prys-Roberts</surname><given-names>C</given-names></name><name><surname>Farndon</surname><given-names>JR</given-names></name></person-group>
<year>2002</year>
<article-title>Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.</article-title>
<source>World J Surg</source>
<volume>26</volume>
<fpage>1037</fpage>
<lpage>1042</lpage>
<pub-id pub-id-type="pmid">12192533</pub-id></element-citation></ref><ref id="pone.0030854-Guo1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>TZ</given-names></name><name><surname>Tinklenberg</surname><given-names>J</given-names></name><name><surname>Oliker</surname><given-names>R</given-names></name><name><surname>Maze</surname><given-names>M</given-names></name></person-group>
<year>1991</year>
<article-title>Central alpha 1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist.</article-title>
<source>Anesthesiology</source>
<volume>75</volume>
<fpage>252</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">1677547</pub-id></element-citation></ref><ref id="pone.0030854-Sheehan1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Sheehan</surname><given-names>KH</given-names></name><name><surname>Amorim</surname><given-names>P</given-names></name><name><surname>Janavs</surname><given-names>J</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.</article-title>
<source>J Clin Psychiatry</source>
<volume>59</volume>
<issue>Suppl 20</issue>
<fpage>22</fpage>
<lpage>33; quiz 34&#x02013;57</lpage>
</element-citation></ref><ref id="pone.0030854-Beck1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name><name><surname>Ball</surname><given-names>R</given-names></name><name><surname>Ranieri</surname><given-names>W</given-names></name></person-group>
<year>1996</year>
<article-title>Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.</article-title>
<source>J Pers Assess</source>
<volume>67</volume>
<fpage>588</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="pmid">8991972</pub-id></element-citation></ref><ref id="pone.0030854-Newton1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newton</surname><given-names>TF</given-names></name><name><surname>De La Garza</surname><given-names>R</given-names><suffix>2nd</suffix></name><name><surname>Kalechstein</surname><given-names>AD</given-names></name><name><surname>Nestor</surname><given-names>L</given-names></name></person-group>
<year>2005</year>
<article-title>Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects.</article-title>
<source>Pharmacol Biochem Behav</source>
<volume>82</volume>
<fpage>90</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">16112720</pub-id></element-citation></ref><ref id="pone.0030854-Chiou1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiou</surname><given-names>WL</given-names></name></person-group>
<year>1978</year>
<article-title>Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level&#x02013;time curve.</article-title>
<source>J Pharmacokinet Biopharm</source>
<volume>6</volume>
<fpage>539</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="pmid">731416</pub-id></element-citation></ref><ref id="pone.0030854-Kirby1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirby</surname><given-names>RS</given-names></name><name><surname>Andersen</surname><given-names>M</given-names></name><name><surname>Gratzke</surname><given-names>P</given-names></name><name><surname>Dahlstrand</surname><given-names>C</given-names></name><name><surname>Hoye</surname><given-names>K</given-names></name></person-group>
<year>2001</year>
<article-title>A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.</article-title>
<source>BJU Int</source>
<volume>87</volume>
<fpage>192</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">11167641</pub-id></element-citation></ref><ref id="pone.0030854-Cohen1"><label>22</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group>
<year>1988</year>
<source>Statistical Power Analysis for the Behavioral Science</source>
<publisher-loc>Hillsdale, N.J.</publisher-loc>
<publisher-name>L. Erlbaum Associates</publisher-name>
</element-citation></ref><ref id="pone.0030854-Shaham1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaham</surname><given-names>Y</given-names></name><name><surname>Shalev</surname><given-names>U</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>De Wit</surname><given-names>H</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>The reinstatement model of drug relapse: history, methodology and major findings.</article-title>
<source>Psychopharmacology (Berl)</source>
<volume>168</volume>
<fpage>3</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">12402102</pub-id></element-citation></ref><ref id="pone.0030854-Woolverton2"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woolverton</surname><given-names>WL</given-names></name></person-group>
<year>1987</year>
<article-title>Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys.</article-title>
<source>Pharmacol Biochem Behav</source>
<volume>26</volume>
<fpage>835</fpage>
<lpage>839</lpage>
<pub-id pub-id-type="pmid">3496618</pub-id></element-citation></ref><ref id="pone.0030854-Fischman1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischman</surname><given-names>MW</given-names></name></person-group>
<year>1989</year>
<article-title>Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs.</article-title>
<source>NIDA Res Monogr</source>
<volume>92</volume>
<fpage>211</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">2512494</pub-id></element-citation></ref><ref id="pone.0030854-Fischman2"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischman</surname><given-names>MW</given-names></name><name><surname>Foltin</surname><given-names>RW</given-names></name></person-group>
<year>1991</year>
<article-title>Utility of subjective-effects measurements in assessing abuse liability of drugs in humans.</article-title>
<source>Br J Addict</source>
<volume>86</volume>
<fpage>1563</fpage>
<lpage>1570</lpage>
<pub-id pub-id-type="pmid">1786488</pub-id></element-citation></ref><ref id="pone.0030854-Haney1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haney</surname><given-names>M</given-names></name><name><surname>Spealman</surname><given-names>R</given-names></name></person-group>
<year>2008</year>
<article-title>Controversies in translational research: drug self-administration.</article-title>
<source>Psychopharmacology (Berl)</source>
<volume>199</volume>
<fpage>403</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="pmid">18283437</pub-id></element-citation></ref><ref id="pone.0030854-Rothman1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothman</surname><given-names>RB</given-names></name><name><surname>Blough</surname><given-names>BE</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name></person-group>
<year>2002</year>
<article-title>Appetite suppressants as agonist substitution therapies for stimulant dependence.</article-title>
<source>Ann N Y Acad Sci</source>
<volume>965</volume>
<fpage>109</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">12105089</pub-id></element-citation></ref><ref id="pone.0030854-Morrison1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morrison</surname><given-names>JH</given-names></name><name><surname>Molliver</surname><given-names>ME</given-names></name><name><surname>Grzanna</surname><given-names>R</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group>
<year>1981</year>
<article-title>The intra-cortical trajectory of the coeruleo-cortical projection in the rat: a tangentially organized cortical afferent.</article-title>
<source>Neuroscience</source>
<volume>6</volume>
<fpage>139</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="pmid">7012664</pub-id></element-citation></ref><ref id="pone.0030854-Schroeder1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>JP</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name><name><surname>Schank</surname><given-names>JR</given-names></name><name><surname>Lyle</surname><given-names>MA</given-names></name><name><surname>Gaval-Cruz</surname><given-names>M</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase.</article-title>
<source>Neuropsychopharmacology</source>
<volume>35</volume>
<fpage>2440</fpage>
<lpage>2449</lpage>
<pub-id pub-id-type="pmid">20736996</pub-id></element-citation></ref><ref id="pone.0030854-Waeber1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waeber</surname><given-names>B</given-names></name><name><surname>Feihl</surname><given-names>F</given-names></name><name><surname>Ruilope</surname><given-names>LM</given-names></name></person-group>
<year>2009</year>
<article-title>Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.</article-title>
<source>Drugs</source>
<volume>69</volume>
<fpage>1761</fpage>
<lpage>1776</lpage>
<pub-id pub-id-type="pmid">19719332</pub-id></element-citation></ref></ref-list></back></article>